Literature DB >> 15388474

Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Dianne B Hoellman1, Glenn A Pankuch, Peter C Appelbaum.   

Abstract

Among 265 methicillin-susceptible and -resistant staphylococci, CB-181963 (CAB-175) had a 50% minimum inhibitory concentration of 2 microg/ml and a 90% minimum inhibitory concentration of 4 microg/ml. All strains except two vancomycin-resistant S. aureus and 5 vancomycin-intermediate S. aureus strains were also susceptible to vancomycin and teicoplanin, and all were susceptible to linezolid, ranbezolid, tigecycline, and quinupristin-dalfopristin. Most methicillin-resistant strains were levofloxacin resistant. CB-181963 was bactericidal against all six methicillin-resistant strains at four times the MIC after 24 h.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388474      PMCID: PMC521906          DOI: 10.1128/AAC.48.10.4037-4039.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

2.  In vitro activity of linezolid against staphylococci.

Authors:  C Cuny; W Witte
Journal:  Clin Microbiol Infect       Date:  2000-06       Impact factor: 8.067

3.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

4.  In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors:  C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

6.  Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

Authors:  F J Schmitz; A C Fluit; S Brisse; J Verhoef; K Köhrer; D Milatovic
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

7.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 8.  Optimal treatment of complicated skin and skin structure infections.

Authors:  R L Nichols
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

9.  Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

Authors:  Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.